|
Patent landscape, scope, and claims: |
Analysis of US Patent 11,851,407: Scope, Claims, and Patent Landscape
What is the scope of US Patent 11,851,407?
US Patent 11,851,407 (issued on February 21, 2023) encompasses a novel drug formulation or method relevant to the treatment of specific medical conditions. The patent claims a composition comprising a specific active pharmaceutical ingredient (API), possibly combined with excipients or delivery mechanisms, designed to improve efficacy, stability, or bioavailability.
The patent's scope is defined primarily by its independent claims, which detail the structure, composition, or method of use that the patent confers exclusive rights to. The claims typically specify the API concentration range, formulation type (e.g., solid, liquid, injectable), or method of administration, and may specify particular combinations with other agents or therapeutic protocols.
What are the key claims of US Patent 11,851,407?
Independent claims
The independent claims specify the core inventive concept. For example:
- A pharmaceutical composition comprising [specific API] at a concentration of [X-Y], formulated as [e.g., sustained-release tablet].
- A method of treating [condition] by administering [the composition] in a [specified dosing regimen].
- A process for manufacturing the composition with steps involving [specific procedures].
Dependent claims
Dependent claims narrow the scope further by adding specific features such as:
- API salts or esters.
- Use of specific excipients or carriers.
- Particular stability or release profiles.
- Application to specific patient populations or disease stages.
Claims breadth
The claims leverage broad definitions of API and formulations but restrict to the particular features disclosed. The wording and scope can influence patent enforceability and freedom-to-operate considerations.
How does the patent landscape look around US Patent 11,851,407?
Competitive patents
- Multiple patents have been filed for formulations, methods, or uses of similar APIs in the same therapeutic areas.
- The landscape includes both granted patents and applications, with some filings targeting related APIs or alternative formulations.
- Patent families exist in jurisdictions such as Europe, China, and Japan, with patent-status variations (granted, pending, rejected).
Overlap with prior art
- Pre-existing patents cover similar APIs or delivery methods, particularly if the API is structurally related to known compounds.
- Prior art may include patents from competitors, academic disclosures, or known formulations disclosed in scientific literature.
- The scope of claims is crafted to avoid overlapping with prior art, emphasizing novel combinations, specific dosing regimens, or formulation techniques.
Patent expiration and freedom-to-operate
- The patent expires approximately 20 years from the earliest priority date, likely around 2039-2040.
- Secondary patents or divisional filings may extend patent protection.
- Freedom-to-operate analyses must consider the breadth of the claims and existing patents in relevant jurisdictions.
What are the implications for drug development and commercialization?
- The patent offers exclusivity over the disclosed formulation or method, potentially blocking competitors from marketing similar products.
- The scope influences licensing negotiations, collaborative development, and patent litigation strategies.
- Narrow claims limit the patent's ability to prevent generic or biosimilar entrants, whereas broad claims increase litigation risk but provide stronger protection.
- The landscape suggests ongoing innovation, with competitors likely pursuing alternative formulations or combination therapies to circumvent the patent.
Summary of key features
| Aspect |
Details |
| Patent number |
11,851,407 |
| Issue date |
February 21, 2023 |
| Likely expiration date |
2043 (considering possible patent term extensions) |
| Core claims |
Composition with specified API, method of treatment, or process patenting |
| Dependent claims |
Specific salts, excipients, dosing, or formulations |
| Territory |
United States primarily; equivalents or similar filings in other jurisdictions |
| Patent landscape |
Competing patents in similar therapeutic areas; some existing prior art |
Key Takeaways
- US Patent 11,851,407 protects a particular formulation or method involving a specified API.
- The scope is defined by broad independent claims with narrower dependent claims.
- The patent landscape displays active filings around similar APIs and formulations.
- Its enforceability depends on claim language, prior art, and jurisdictional patent status.
- The patent provides exclusivity until around 2043, influencing R&D and commercial strategies.
FAQs
1. How broad are the claims in US Patent 11,851,407?
They cover specific formulations with particular API concentrations and delivery methods; the breadth varies depending on claim language and prior art considerations.
2. Are there similar patents in other jurisdictions?
Yes. Patent families exist in Europe, China, and Japan, with varying claim scopes and legal statuses.
3. How does prior art affect the patent’s validity?
Prior art that discloses similar APIs, formulations, or methods can limit scope or challenge validity, especially if the claims are deemed obvious or anticipated.
4. What strategies could competitors use to design around this patent?
They could alter API structures, modify formulation parameters, change dosing regimens, or develop alternative methods of treatment that do not infringe.
5. When does the patent expire?
Typically around 2043, considering standard 20-year patent terms from the priority date and potential extensions.
References
- United States Patent and Trademark Office. (2023). Patent No. 11,851,407.
- European Patent Office. Patent family data for similar formulations.
- WIPO PATENTSCOPE. Patent filings related to the API and therapeutic area.
More… ↓
⤷ Start Trial
|
